Poor sensitivity for localized PCa was a major drawback for ACPP [15, 16], and its presence in extraprostatic tissue was another reason why its clinical use as a biomarker of PCa diminished [17, 18]. The gene discussed is ACP3; the disease is posterior cortical atrophy.